Loading stock data…
INMB
$1.51+0.08 (+5.59%)
Market ClosedLast close May 1
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
INmune Bio Inc. in the Healthcare sector is trading at $1.51. The stock is currently near its 52-week low of $1.09, remaining 14.2% below its 200-day moving average. Technical signals show neutral RSI of 65 and bullish MACD crossover, explaining why INMB maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 65) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.51
Potential Upside
5%
Whystock Fair Value$1.59
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic ma...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$38.02M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.89
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-235.96%
Volume
Today's trading volume
197,359
Recent News
INmune Bio (NASDAQ:INMB) Will Have To Spend Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
INmune Bio, Inc. Q4 2025 Earnings Call Summary
Moby summary of INmune Bio, Inc.'s Q4 2025 earnings call
INmune Bio Inc (INMB) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
INmune Bio Inc (INMB) reports significant progress in clinical trials and regulatory plans, despite increased net loss and asset impairment.
INmune Bio submits pre-submission package for CORDStrom with MHRA
INmune Bio (INMB) has formally submitted its pre-submission package for CORDStrom with the United Kingdom’s Medicines and Healthcare Products Regulatory Agency. This early engagement step is designed to solicit targeted scientific, regulatory, and procedural feedback, streamlining the full Marketing Authorization Application process and potentially shortening time to market for what could become the first systemic therapy for this devastating “butterfly skin” disease. INmune Bio has completed th
INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
INmune Bio (INMB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.